Hospital
Charleston Area Medical Center INC
Charleston Area Medical Center INC was paid $199.84M by Medicaid between Jan 2018 and Dec 2024, across 736 billing codes. Its largest line is 99285, emergency room visit (most serious) — 12% of everything it billed.
33Billing provider infoCHARLESTON AREA MEDICAL CENTER INC
CHARLESTON, WV 25301
CHARLESTON, WV 25301
33aNPI1952390239assigned 10/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$199.84M
24GClaims4,024,224
24DCodes billed736
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#1 of 26
Median peer was paid$18.33M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 712,859 | $52.36M | |
| 2019 | 540,421 | $43.02M | |
| 2020 | 683,852 | $46.52M | |
| 2021 | 682,410 | $21.07M | |
| 2022 | 452,338 | $12.39M | |
| 2023 | 525,321 | $13.69M | |
| 2024incomplete | 427,023 | $10.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 58,239 | 49,719 | $24.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.1% | 104,236 | 92,738 | $18.22M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.5% | 95,002 | 86,470 | $9.09M |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.6% | 6,371 | 5,098 | $7.25M |
| J9271 | Injection, pembrolizumab, 1 mg | 2.5% | 907 | 580 | $4.97M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 15,623 | 13,887 | $4.12M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 257,049 | 209,267 | $3.76M |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 144,015 | 98,845 | $2.82M |
| G0378 | Hospital observation service, per hour | 1.3% | 6,926 | 5,721 | $2.65M |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 1.3% | 40,746 | 28,681 | $2.58M |
| 83605 | 1.3% | 139,468 | 108,264 | $2.52M | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.1% | 59,235 | 43,397 | $2.30M |
724 more codes
| 80047 | 1.1% | 115,392 | $2.14M | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.0% | 8,019 | $2.03M |
| J2704 | Injection, propofol, 10 mg | <1% | 33,274 | $1.99M |
| 80053 | Comprehensive metabolic panel | <1% | 118,339 | $1.93M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 11,581 | $1.81M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,549 | $1.81M |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 96,972 | $1.78M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 95,669 | $1.72M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 19,926 | $1.65M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 927 | $1.62M |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 31,681 | $1.61M |
| 93458 | <1% | 2,319 | $1.54M | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 20,070 | $1.54M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 11,731 | $1.50M |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,958 | $1.46M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 5,216 | $1.44M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 43,641 | $1.41M |
| 84484 | <1% | 59,175 | $1.34M | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 46,582 | $1.31M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 23,140 | $1.29M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 31,627 | $1.27M |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 29,107 | $1.24M |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 63,894 | $1.22M |
| 81001 | <1% | 99,236 | $1.21M | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 55,425 | $1.15M |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 59,472 | $1.15M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 34,049 | $1.14M |
| 80076 | <1% | 71,242 | $1.14M | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13,670 | $1.14M |
| 77386 | <1% | 4,201 | $1.13M | |
| 81025 | <1% | 21,838 | $1.07M | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,860 | $1.04M |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,923 | $1.02M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 6,417 | $983K |
| 82948 | <1% | 11,975 | $979K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 34,015 | $976K |
| 47562 | <1% | 360 | $924K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 9,039 | $879K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 4,219 | $872K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 12,431 | $871K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 470 | $813K |
| 80074 | <1% | 16,695 | $810K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 21,548 | $790K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 21,529 | $789K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 15,950 | $772K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,033 | $745K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15,889 | $733K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 35,052 | $720K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,709 | $680K |
| 85610 | <1% | 54,477 | $677K | |
| 83690 | <1% | 46,975 | $669K | |
| 85027 | <1% | 38,799 | $665K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,782 | $642K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 43,010 | $631K |
| 80061 | Lipid panel | <1% | 39,780 | $623K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12,076 | $622K |
| J3490 | Unclassified drugs | <1% | 2,975 | $615K |
| 84703 | <1% | 25,869 | $558K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,221 | $544K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,338 | $544K |
| 93975 | <1% | 3,025 | $543K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 23,465 | $533K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 4,435 | $525K |
| 43282 | <1% | 489 | $492K | |
| 88307 | <1% | 2,863 | $477K | |
| 87040 | <1% | 18,959 | $471K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 30,358 | $469K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 11,964 | $465K |
| 81514 | <1% | 2,466 | $456K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13,961 | $443K |
| 71045 | Radiologic examination, chest; single view | <1% | 19,966 | $440K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 22,117 | $439K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,575 | $436K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 8,389 | $435K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 4,350 | $434K |
| 83735 | <1% | 39,720 | $429K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,410 | $422K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 17,081 | $420K |
| 76830 | Ultrasound, transvaginal | <1% | 5,294 | $405K |
| 86850 | <1% | 15,988 | $401K | |
| 88304 | <1% | 3,255 | $394K | |
| 73564 | <1% | 5,232 | $387K | |
| 88342 | <1% | 6,341 | $383K | |
| 59025 | Fetal non-stress test | <1% | 8,286 | $373K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,206 | $362K |
| 74022 | <1% | 10,090 | $361K | |
| 86900 | <1% | 16,096 | $345K | |
| 87507 | <1% | 1,386 | $343K | |
| 86901 | <1% | 16,087 | $342K | |
| 85730 | <1% | 17,100 | $338K | |
| 96415 | <1% | 3,558 | $327K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 3,764 | $325K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 608 | $324K |
| 87070 | <1% | 18,305 | $322K | |
| 86140 | <1% | 26,909 | $318K | |
| 71250 | <1% | 3,580 | $312K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,736 | $299K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 15,056 | $299K |
| 80305 | <1% | 10,194 | $297K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 3,466 | $296K |
| 87480 | <1% | 10,419 | $295K | |
| 87660 | <1% | 10,378 | $295K | |
| 87510 | <1% | 10,378 | $294K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 5,880 | $294K |
| 74178 | <1% | 827 | $292K | |
| 76826 | <1% | 2,648 | $291K | |
| 93971 | <1% | 3,722 | $289K | |
| 96417 | <1% | 2,634 | $289K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,942 | $282K |
| 43775 | <1% | 616 | $282K | |
| 93017 | <1% | 4,494 | $280K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,112 | $277K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 290 | $276K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,787 | $273K |
| Q9951 | Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml | <1% | 1,176 | $273K |
| 84439 | <1% | 20,124 | $270K | |
| 96367 | <1% | 4,477 | $269K | |
| 99205 | Prolong outpt/office vis | <1% | 12,344 | $268K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 14,669 | $265K |
| 80320 | <1% | 6,178 | $263K | |
| 93880 | <1% | 3,823 | $262K | |
| 72141 | <1% | 1,027 | $260K | |
| 83880 | <1% | 8,167 | $260K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,353 | $258K |
| 77336 | <1% | 2,297 | $252K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 4,440 | $247K |
| 82607 | <1% | 14,991 | $245K | |
| 59050 | <1% | 3,696 | $243K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,508 | $233K |
| J1815 | Injection, insulin, per 5 units | <1% | 8,191 | $231K |
| C1769 | Guide wire | <1% | 4,059 | $221K |
| 95816 | <1% | 1,203 | $221K | |
| 76536 | <1% | 3,425 | $221K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 7,754 | $218K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 907 | $215K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,974 | $208K |
| 87205 | <1% | 7,894 | $208K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,327 | $206K |
| 84100 | <1% | 12,346 | $205K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,238 | $205K |
| 85379 | <1% | 9,678 | $203K | |
| 73130 | <1% | 5,200 | $201K | |
| 84702 | <1% | 6,918 | $200K | |
| 93970 | <1% | 2,044 | $199K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 9,778 | $198K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,942 | $195K |
| 87186 | <1% | 10,294 | $194K | |
| 82803 | <1% | 7,755 | $191K | |
| 70498 | <1% | 1,178 | $190K | |
| 73030 | <1% | 5,585 | $190K | |
| 70486 | <1% | 1,282 | $189K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,888 | $186K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,362 | $182K |
| 70491 | <1% | 1,250 | $172K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,843 | $171K |
| 87902 | <1% | 911 | $167K | |
| 76825 | <1% | 1,080 | $167K | |
| 73610 | <1% | 5,635 | $166K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 19,236 | $165K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 262 | $164K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 139 | $162K |
| 73630 | <1% | 5,567 | $161K | |
| C1758 | Catheter, ureteral | <1% | 814 | $154K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,917 | $153K |
| 87522 | Neg quan hep c or qual rna | <1% | 4,707 | $153K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 380 | $152K |
| 72110 | <1% | 4,303 | $146K | |
| 84466 | <1% | 10,867 | $144K | |
| 86780 | <1% | 8,932 | $142K | |
| 87450 | <1% | 3,651 | $141K | |
| 81003 | <1% | 23,059 | $140K | |
| 88185 | <1% | 1,836 | $139K | |
| 73110 | <1% | 4,482 | $139K | |
| 96376 | <1% | 3,489 | $139K | |
| 86481 | <1% | 1,612 | $137K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,322 | $135K |
| 76000 | <1% | 1,085 | $135K | |
| 85652 | <1% | 15,585 | $133K | |
| 96411 | <1% | 814 | $132K | |
| 82728 | <1% | 9,063 | $132K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,217 | $129K |
| 70496 | <1% | 747 | $129K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 865 | $128K |
| 80329 | <1% | 1,516 | $128K | |
| 87075 | <1% | 1,541 | $127K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,312 | $127K |
| 87077 | <1% | 6,347 | $127K | |
| 72158 | <1% | 269 | $124K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,919 | $124K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 767 | $121K |
| 80335 | <1% | 1,430 | $120K | |
| 76770 | <1% | 1,850 | $119K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,735 | $119K |
| 93925 | <1% | 1,324 | $118K | |
| 52356 | <1% | 100 | $118K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 140 | $116K |
| 84144 | <1% | 3,319 | $114K | |
| 76642 | <1% | 2,250 | $110K | |
| 10060 | <1% | 1,289 | $110K | |
| 96401 | <1% | 974 | $107K | |
| 93922 | <1% | 3,629 | $107K | |
| 74018 | <1% | 4,159 | $107K | |
| 96368 | <1% | 1,381 | $104K | |
| 83540 | <1% | 11,551 | $104K | |
| 84132 | <1% | 2,505 | $103K | |
| 73502 | <1% | 3,942 | $102K | |
| 76827 | <1% | 1,136 | $100K | |
| 82746 | <1% | 6,891 | $99K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,084 | $99K |
| 20610 | <1% | 1,945 | $97K | |
| C1781 | Mesh (implantable) | <1% | 507 | $96K |
| 82330 | <1% | 4,165 | $96K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,221 | $94K |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 520 | $93K |
| 96402 | <1% | 354 | $92K | |
| 86920 | <1% | 1,641 | $92K | |
| 80050 | General health panel | <1% | 2,827 | $90K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 2,696 | $89K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,644 | $88K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,187 | $88K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,308 | $88K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,596 | $85K |
| 72100 | <1% | 3,287 | $84K | |
| 77334 | <1% | 665 | $84K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 607 | $83K |
| 77301 | <1% | 132 | $82K | |
| 76775 | <1% | 1,955 | $80K | |
| 36430 | <1% | 860 | $79K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 128 | $79K |
| 80179 | <1% | 6,645 | $78K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,636 | $78K |
| 58661 | <1% | 26 | $78K | |
| 70487 | <1% | 144 | $74K | |
| 77066 | Tomosynthesis, mammo | <1% | 973 | $74K |
| 12001 | <1% | 1,071 | $72K | |
| 84403 | <1% | 2,899 | $72K | |
| 82140 | <1% | 4,263 | $72K | |
| C1753 | Catheter, intravascular ultrasound | <1% | 103 | $72K |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 523 | $69K |
| 95819 | <1% | 258 | $69K | |
| 76870 | <1% | 1,062 | $68K | |
| 72156 | <1% | 170 | $68K | |
| 86803 | <1% | 3,120 | $68K | |
| 97161 | <1% | 1,706 | $68K | |
| 75574 | <1% | 854 | $68K | |
| 77300 | <1% | 385 | $67K | |
| 94729 | <1% | 2,555 | $66K | |
| 81596 | <1% | 667 | $65K | |
| 73090 | <1% | 1,657 | $64K | |
| 72072 | <1% | 1,779 | $64K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,592 | $64K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 592 | $62K |
| 80143 | <1% | 5,344 | $62K | |
| 82150 | <1% | 2,317 | $62K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,141 | $61K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,082 | $61K |
| 74019 | <1% | 2,716 | $61K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,235 | $61K |
| 94726 | <1% | 2,289 | $61K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 595 | $60K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,095 | $60K |
| 70320 | <1% | 206 | $60K | |
| 82550 | <1% | 4,716 | $58K | |
| 73590 | <1% | 2,066 | $57K | |
| 90715 | <1% | 1,308 | $57K | |
| 82565 | <1% | 5,891 | $56K | |
| 88184 | <1% | 1,834 | $56K | |
| 88312 | <1% | 66 | $56K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 564 | $54K |
| 87102 | <1% | 1,002 | $54K | |
| 83615 | <1% | 4,164 | $54K | |
| 82947 | <1% | 7,456 | $54K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 28 | $53K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,228 | $52K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 573 | $52K |
| 82784 | <1% | 3,707 | $52K | |
| 83970 | <1% | 1,881 | $52K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 68 | $52K |
| 73080 | <1% | 1,583 | $52K | |
| 84145 | <1% | 2,942 | $52K | |
| 88341 | <1% | 704 | $52K | |
| 86038 | <1% | 3,163 | $51K | |
| 58571 | <1% | 38 | $51K | |
| 73221 | <1% | 280 | $50K | |
| 52000 | <1% | 280 | $49K | |
| 12011 | <1% | 349 | $49K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,559 | $49K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 585 | $49K |
| 76001 | <1% | 124 | $49K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 428 | $48K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,607 | $47K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 288 | $47K |
| 93976 | <1% | 707 | $47K | |
| 72040 | <1% | 1,452 | $47K | |
| 82570 | <1% | 6,558 | $47K | |
| 86706 | <1% | 2,819 | $46K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,616 | $46K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,019 | $46K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 133 | $46K |
| 77338 | <1% | 213 | $46K | |
| 86762 | <1% | 1,640 | $45K | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 509 | $45K |
| 94060 | <1% | 1,613 | $45K | |
| 83520 | <1% | 1,904 | $45K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 154 | $44K |
| 87338 | <1% | 2,636 | $44K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,016 | $44K |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 369 | $43K |
| 84550 | <1% | 3,583 | $43K | |
| 84520 | <1% | 1,646 | $42K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,505 | $42K |
| 84153 | <1% | 1,912 | $42K | |
| 74183 | <1% | 178 | $41K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,981 | $40K |
| 86708 | <1% | 1,497 | $40K | |
| 90686 | <1% | 3,142 | $40K | |
| 93926 | <1% | 553 | $40K | |
| 77065 | Tomosynthesis, mammo | <1% | 823 | $39K |
| 76801 | <1% | 551 | $39K | |
| 72050 | <1% | 787 | $39K | |
| 73562 | <1% | 1,150 | $39K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 91 | $39K |
| 82270 | <1% | 2,471 | $39K | |
| 77080 | <1% | 650 | $37K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,843 | $37K |
| 86256 | <1% | 847 | $37K | |
| 86003 | <1% | 725 | $36K | |
| 78264 | <1% | 205 | $36K | |
| 93613 | <1% | 16 | $35K | |
| G0143 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision | <1% | 1,186 | $35K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 383 | $35K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 686 | $34K |
| 80164 | <1% | 1,541 | $34K | |
| 82105 | <1% | 1,292 | $34K | |
| 97162 | <1% | 788 | $33K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 302 | $33K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 488 | $33K |
| 69210 | <1% | 328 | $33K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 674 | $33K |
| 87340 | <1% | 2,112 | $33K | |
| 74420 | <1% | 348 | $33K | |
| 95886 | <1% | 542 | $32K | |
| 72052 | <1% | 583 | $32K | |
| 90714 | <1% | 1,909 | $31K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,117 | $31K |
| 82378 | <1% | 1,137 | $31K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,910 | $30K |
| 73552 | <1% | 927 | $30K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,378 | $30K |
| 82977 | <1% | 1,974 | $29K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 268 | $29K |
| 76937 | <1% | 663 | $29K | |
| 76820 | <1% | 531 | $29K | |
| 84156 | <1% | 3,774 | $29K | |
| 86704 | <1% | 1,763 | $29K | |
| 84295 | <1% | 1,208 | $29K | |
| 78227 | <1% | 110 | $28K | |
| 82043 | <1% | 3,239 | $28K | |
| 84146 | <1% | 985 | $28K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 405 | $28K |
| 83002 | <1% | 1,308 | $28K | |
| 86235 | <1% | 348 | $28K | |
| 86376 | <1% | 1,569 | $27K | |
| 84480 | <1% | 1,791 | $26K | |
| 80069 | <1% | 3,780 | $26K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,210 | $25K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 585 | $25K |
| 73700 | <1% | 138 | $25K | |
| 84112 | <1% | 304 | $25K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,472 | $25K |
| 88302 | <1% | 108 | $24K | |
| 88360 | <1% | 236 | $24K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 311 | $24K |
| 77072 | <1% | 1,019 | $24K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,436 | $24K |
| 73140 | <1% | 667 | $24K | |
| 84481 | <1% | 1,297 | $23K | |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | <1% | 974 | $23K |
| 82670 | <1% | 782 | $23K | |
| 82533 | <1% | 679 | $23K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 387 | $23K |
| 93798 | <1% | 937 | $23K | |
| 64483 | <1% | 91 | $23K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,050 | $23K |
| 84450 | <1% | 909 | $22K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,152 | $22K |
| 58558 | <1% | 75 | $22K | |
| 86225 | <1% | 1,135 | $22K | |
| 84460 | <1% | 894 | $22K | |
| 93270 | <1% | 356 | $21K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 129 | $21K |
| 12002 | <1% | 351 | $21K | |
| 76377 | <1% | 286 | $21K | |
| 87529 | <1% | 441 | $21K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 81 | $20K |
| 73560 | <1% | 1,289 | $20K | |
| 86304 | <1% | 554 | $20K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 84 | $20K |
| 29125 | <1% | 223 | $20K | |
| 94010 | <1% | 869 | $20K | |
| 93226 | <1% | 116 | $19K | |
| 83655 | <1% | 1,725 | $19K | |
| 84305 | <1% | 962 | $19K | |
| 86800 | <1% | 1,011 | $19K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 240 | $19K |
| 82103 | <1% | 660 | $19K | |
| 54161 | <1% | 20 | $18K | |
| 82785 | <1% | 869 | $18K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 33 | $18K |
| 78226 | <1% | 115 | $18K | |
| 80197 | <1% | 2,706 | $18K | |
| 83001 | <1% | 817 | $17K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 681 | $17K |
| 85014 | <1% | 1,435 | $17K | |
| 82397 | <1% | 620 | $17K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,999 | $17K |
| 73060 | <1% | 622 | $17K | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 241 | $17K |
| 83525 | <1% | 995 | $17K | |
| 82040 | <1% | 31 | $17K | |
| 88142 | <1% | 505 | $16K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 206 | $16K |
| 72131 | <1% | 31 | $16K | |
| 76882 | <1% | 389 | $16K | |
| 31575 | <1% | 227 | $16K | |
| 93978 | <1% | 316 | $15K | |
| 71101 | <1% | 357 | $15K | |
| 71271 | <1% | 276 | $15K | |
| 64493 | <1% | 53 | $15K | |
| 80055 | <1% | 441 | $15K | |
| 85044 | <1% | 1,671 | $15K | |
| 83516 | <1% | 1,218 | $15K | |
| 88173 | <1% | 406 | $15K | |
| 51798 | <1% | 1,227 | $15K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 36 | $15K |
| 84436 | <1% | 986 | $15K | |
| 72146 | <1% | 74 | $14K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 220 | $14K |
| 36561 | <1% | 38 | $14K | |
| 86308 | <1% | 928 | $14K | |
| 82657 | <1% | 213 | $14K | |
| 73070 | <1% | 664 | $14K | |
| 72170 | <1% | 439 | $14K | |
| 86431 | <1% | 1,464 | $13K | |
| 96379 | <1% | 143 | $13K | |
| 82248 | <1% | 1,567 | $13K | |
| 43235 | <1% | 20 | $13K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 81 | $12K |
| 64494 | <1% | 49 | $12K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,806 | $12K |
| 87324 | <1% | 157 | $12K | |
| 86665 | <1% | 484 | $12K | |
| 78306 | <1% | 39 | $11K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 499 | $11K |
| 10061 | <1% | 67 | $11K | |
| 86709 | <1% | 421 | $11K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 607 | $11K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 568 | $11K |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 240 | $10K |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 68 | $10K |
| 96523 | <1% | 403 | $10K | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 798 | $10K |
| 88300 | <1% | 295 | $10K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 199 | $10K |
| 80202 | <1% | 242 | $10K | |
| 95956 | <1% | 16 | $10K | |
| 81599 | <1% | 168 | $10K | |
| 82652 | <1% | 316 | $10K | |
| 72081 | <1% | 383 | $10K | |
| 82390 | <1% | 450 | $10K | |
| 80177 | <1% | 290 | $9K | |
| 84134 | <1% | 374 | $9K | |
| 80178 | <1% | 347 | $9K | |
| 85018 | <1% | 1,065 | $9K | |
| 92083 | <1% | 394 | $9K | |
| 89051 | <1% | 520 | $9K | |
| 95716 | <1% | 18 | $9K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 490 | $9K |
| 87206 | <1% | 705 | $9K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 317 | $8K |
| 82010 | <1% | 423 | $8K | |
| 74174 | <1% | 112 | $8K | |
| 51701 | <1% | 176 | $8K | |
| 88143 | <1% | 272 | $8K | |
| 86618 | <1% | 456 | $8K | |
| 76885 | <1% | 60 | $8K | |
| 86334 | <1% | 361 | $7K | |
| 87449 | <1% | 374 | $7K | |
| 87081 | <1% | 278 | $7K | |
| 83883 | <1% | 196 | $7K | |
| 95953 | <1% | 13 | $7K | |
| 93660 | <1% | 85 | $7K | |
| 86403 | <1% | 313 | $7K | |
| 93000 | <1% | 381 | $7K | |
| 83010 | <1% | 170 | $7K | |
| Q3014 | Telehealth originating site facility fee | <1% | 236 | $7K |
| 64721 | <1% | 29 | $7K | |
| 84402 | <1% | 334 | $6K | |
| 84479 | <1% | 232 | $6K | |
| 83721 | <1% | 217 | $6K | |
| 88311 | <1% | 282 | $6K | |
| 86664 | <1% | 270 | $6K | |
| 90677 | <1% | 80 | $6K | |
| 82172 | <1% | 116 | $6K | |
| 52310 | <1% | 40 | $6K | |
| 87799 | <1% | 424 | $6K | |
| 84165 | <1% | 547 | $6K | |
| 86663 | <1% | 273 | $6K | |
| 76942 | <1% | 95 | $6K | |
| 49083 | <1% | 68 | $5K | |
| 92133 | <1% | 697 | $5K | |
| 94664 | <1% | 139 | $5K | |
| 86255 | <1% | 500 | $5K | |
| 71100 | <1% | 159 | $5K | |
| 87497 | <1% | 383 | $5K | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 56 | $5K |
| 86200 | <1% | 540 | $5K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 192 | $5K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 160 | $5K |
| 87641 | <1% | 234 | $5K | |
| 83993 | <1% | 169 | $5K | |
| 70360 | <1% | 261 | $5K | |
| 86696 | <1% | 286 | $5K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 133 | $5K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 302 | $5K |
| 88112 | <1% | 138 | $5K | |
| 73120 | <1% | 166 | $5K | |
| 96409 | <1% | 88 | $5K | |
| 19083 | <1% | 27 | $5K | |
| 90636 | <1% | 93 | $5K | |
| 99152 | <1% | 1,112 | $5K | |
| J3364 | Injection, urokinase, 5000 iu vial | <1% | 45 | $5K |
| 70355 | <1% | 57 | $5K | |
| 73000 | <1% | 181 | $5K | |
| 93225 | <1% | 238 | $4K | |
| 73522 | <1% | 178 | $4K | |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 39 | $4K |
| 64495 | <1% | 17 | $4K | |
| 25600 | <1% | 26 | $4K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 474 | $4K |
| 92557 | <1% | 80 | $4K | |
| 93312 | <1% | 83 | $4K | |
| 86160 | <1% | 193 | $4K | |
| 0003M | <1% | 90 | $4K | |
| 73718 | <1% | 16 | $4K | |
| A9270 | Non-covered item or service | <1% | 26,427 | $4K |
| 86364 | <1% | 427 | $4K | |
| 82044 | <1% | 260 | $4K | |
| 86300 | <1% | 103 | $4K | |
| 36600 | <1% | 185 | $4K | |
| 73620 | <1% | 133 | $3K | |
| 87150 | <1% | 17 | $3K | |
| 93882 | <1% | 40 | $3K | |
| 86695 | <1% | 286 | $3K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 85 | $3K |
| 99153 | Mod sedat endo service >5yrs | <1% | 727 | $3K |
| 72190 | <1% | 51 | $3K | |
| 93350 | <1% | 14 | $3K | |
| 97602 | <1% | 402 | $3K | |
| 97116 | <1% | 516 | $3K | |
| 90670 | <1% | 73 | $3K | |
| 62270 | <1% | 29 | $3K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 1,242 | $3K |
| 31231 | <1% | 30 | $3K | |
| 90732 | <1% | 83 | $3K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 75 | $3K |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 241 | $3K |
| 82627 | <1% | 112 | $3K | |
| 86147 | <1% | 68 | $3K | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 42 | $3K |
| S9444 | Parenting classes, non-physician provider, per session | <1% | 273 | $3K |
| 80081 | <1% | 40 | $3K | |
| 77280 | <1% | 19 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 144 | $2K |
| J9206 | Injection, irinotecan, 20 mg | <1% | 50 | $2K |
| 82679 | <1% | 114 | $2K | |
| 84445 | <1% | 58 | $2K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 24 | $2K |
| 80230 | <1% | 91 | $2K | |
| 74220 | <1% | 73 | $2K | |
| 83630 | <1% | 99 | $2K | |
| 99195 | <1% | 47 | $2K | |
| 92611 | <1% | 26 | $2K | |
| 97165 | <1% | 101 | $2K | |
| 76813 | <1% | 33 | $2K | |
| 70480 | <1% | 12 | $2K | |
| 88313 | <1% | 29 | $2K | |
| 51702 | <1% | 59 | $2K | |
| 36590 | <1% | 16 | $2K | |
| 99201 | <1% | 45 | $2K | |
| C1729 | Catheter, drainage | <1% | 265 | $2K |
| 74230 | <1% | 12 | $2K | |
| 95700 | <1% | 20 | $2K | |
| 82247 | <1% | 163 | $2K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 67 | $2K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 169 | $2K |
| 86039 | <1% | 150 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 78 | $2K |
| 92579 | <1% | 27 | $2K | |
| 72220 | <1% | 31 | $2K | |
| 77370 | <1% | 15 | $2K | |
| 92134 | <1% | 191 | $1K | |
| 96377 | <1% | 55 | $1K | |
| 97802 | <1% | 27 | $1K | |
| 82465 | <1% | 41 | $1K | |
| 83921 | <1% | 63 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 687 | $1K |
| 80347 | <1% | 401 | $1K | |
| 80366 | <1% | 77 | $1K | |
| 84478 | <1% | 38 | $1K | |
| 77470 | <1% | 13 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 29 | $1K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 34 | $1K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 33 | $1K |
| 29515 | <1% | 12 | $1K | |
| 93289 | <1% | 143 | $1K | |
| 84300 | <1% | 145 | $1K | |
| 83521 | <1% | 120 | $1K | |
| 95913 | <1% | 12 | $1K | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 80 | $988.87 |
| 97166 | <1% | 14 | $986.03 | |
| 81237 | <1% | 45 | $980.00 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 14 | $957.19 |
| 82610 | <1% | 57 | $953.93 | |
| 82024 | <1% | 28 | $921.44 | |
| 95911 | <1% | 17 | $903.00 | |
| 80156 | <1% | 32 | $877.72 | |
| 72114 | <1% | 12 | $876.00 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 123 | $873.38 |
| 86146 | <1% | 12 | $866.03 | |
| 83021 | <1% | 14 | $864.66 | |
| 83704 | <1% | 39 | $862.87 | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 13 | $852.25 |
| 82436 | <1% | 113 | $850.76 | |
| 83020 | <1% | 14 | $848.60 | |
| C1763 | Connective tissue, non-human (includes synthetic) | <1% | 13 | $839.00 |
| 83789 | <1% | 90 | $836.38 | |
| 86769 | <1% | 29 | $836.21 | |
| 87899 | <1% | 54 | $834.20 | |
| 86870 | <1% | 14 | $809.54 | |
| 84133 | <1% | 113 | $792.56 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 122 | $764.61 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 131 | $764.61 |
| 84432 | <1% | 40 | $738.11 | |
| 80364 | <1% | 185 | $731.10 | |
| 58100 | <1% | 12 | $715.50 | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 18 | $681.86 |
| 86812 | <1% | 31 | $678.28 | |
| 76506 | <1% | 12 | $676.40 | |
| 92552 | <1% | 39 | $674.70 | |
| 36000 | <1% | 44 | $653.61 | |
| 76818 | <1% | 22 | $630.15 | |
| 92567 | <1% | 41 | $619.90 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 215 | $594.45 |
| 93288 | <1% | 119 | $591.52 | |
| 82077 | <1% | 3,132 | $575.21 | |
| 73565 | <1% | 25 | $535.50 | |
| 87653 | <1% | 17 | $495.82 | |
| 87517 | <1% | 14 | $485.78 | |
| 86301 | <1% | 28 | $432.55 | |
| 88108 | <1% | 21 | $429.00 | |
| 85597 | <1% | 24 | $389.94 | |
| 86593 | <1% | 94 | $352.05 | |
| 83550 | <1% | 63 | $340.65 | |
| 82668 | <1% | 31 | $327.45 | |
| 81015 | <1% | 107 | $303.22 | |
| 86677 | <1% | 12 | $291.48 | |
| 83498 | <1% | 13 | $285.37 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 249 | $271.47 |
| 80051 | <1% | 88 | $260.43 | |
| 0077U | <1% | 325 | $256.47 | |
| 84630 | <1% | 27 | $248.65 | |
| 82951 | <1% | 15 | $247.07 | |
| 85613 | <1% | 27 | $242.20 | |
| 90656 | <1% | 33 | $234.67 | |
| 84425 | <1% | 12 | $220.75 | |
| 84410 | <1% | 14 | $207.27 | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 14 | $205.47 |
| 36902 | <1% | 13 | $196.00 | |
| 90662 | <1% | 123 | $193.85 | |
| 83090 | <1% | 13 | $189.76 | |
| 86625 | <1% | 17 | $186.00 | |
| 94760 | <1% | 149 | $178.93 | |
| 73100 | <1% | 20 | $172.00 | |
| 86705 | <1% | 14 | $167.76 | |
| 84446 | <1% | 12 | $164.20 | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 13 | $154.99 |
| 86787 | <1% | 15 | $145.24 | |
| 87116 | <1% | 17 | $136.30 | |
| 87045 | <1% | 17 | $133.88 | |
| 80299 | <1% | 32 | $132.64 | |
| 86231 | <1% | 14 | $126.87 | |
| 84155 | <1% | 26 | $117.23 | |
| 72070 | <1% | 12 | $116.61 | |
| 85384 | <1% | 15 | $111.93 | |
| 83695 | <1% | 33 | $110.82 | |
| 83930 | <1% | 18 | $87.60 | |
| 82340 | <1% | 16 | $73.95 | |
| D0140 | Limited oral evaluation - problem focused | <1% | 22 | $70.00 |
| 82310 | <1% | 15 | $58.67 | |
| 83935 | <1% | 17 | $52.59 | |
| 85347 | <1% | 44 | $47.92 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 119 | $35.66 |
| 82374 | <1% | 58 | $26.80 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 793 | $23.04 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 767 | $21.63 |
| 82435 | <1% | 57 | $20.93 | |
| G0008 | Administration of influenza virus vaccine | <1% | 15 | $18.90 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 205 | $17.94 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 54 | $13.66 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 170 | $9.82 |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 21 | $7.38 |
| 75571 | <1% | 31 | $3.94 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 294 | $3.77 |
| C1788 | Port, indwelling (implantable) | <1% | 54 | $3.17 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 61 | $0.85 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 26 | $0.51 |
| J2598 | Injection, vasopressin, 1 unit | <1% | 12 | $0.18 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 28 | $0.07 |
| 90674 | <1% | 13 | $0.06 | |
| 80354 | 0% | 110 | $0.00 | |
| J0184 | Injection, amisulpride, 1 mg | 0% | 18 | $0.00 |
| C9250 | Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 ml | 0% | 32 | $0.00 |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOVIS, CHAD (VP OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Camc Plateau Medical Center, INC. | Oak Hill, WV | $3.07M |
| Camc Greenbrier Valley Medical Center INC | Ronceverte, WV | $2.36M |
| Camc Greenbrier Valley Medical Center INC | Ronceverte, WV | $795K |
| Camc Greenbrier Valley Medical Center, INC. | Ronceverte, WV | $23K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.